Truist Financial’s Cytokinetics CYTK Stock Holding History

Truist Financial’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$588K	Buy	+6,904	New	+$496K	﹤0.01%	2099
2022 Q1	–	Sell	-13,093	Closed	-$597K	–	2706
2021 Q4	$597K	Sell	13,093 -41	-0.3%	-$1.58K	﹤0.01%	1918
2021 Q3	$470K	Sell	13,134 -19	-0.1%	-$559	﹤0.01%	2040
2021 Q2	$260K	Sell	13,153 -15	-0.1%	-$352	﹤0.01%	2452
2021 Q1	$306K	Buy	13,168 +828	+7%	+$17.7K	﹤0.01%	2273
2020 Q4	$256K	Buy	12,340 +152	+1%	+$2.78K	﹤0.01%	2250
2020 Q3	$264K	Buy	12,188 +2,941	+32%	+$68.8K	﹤0.01%	2107
2020 Q2	$218K	Buy	+9,247	New	+$173K	﹤0.01%	2136

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Truist Financial's CYTK Position: Q2 2026 in Review

Truist Financial opened a new position in Cytokinetics (CYTK) in Q2 2026: 6,904 shares worth $588K. The stake represents ﹤0.01% of the portfolio and ranks #2099 among its holdings. This is a return to the name: Truist Financial previously reported a position in CYTK as recently as Q4 2021.

Truist Financial first reported a position in CYTK in Q2 2020 and has held it in 8 quarters since. The position peaked at $597K in Q4 2021. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Truist Financial held 6,904 shares of Cytokinetics worth $588K as of Q2 2026.
Cytokinetics was a new Truist Financial position in Q2 2026.
Cytokinetics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2099 holding.
Truist Financial first reported a position in Cytokinetics in Q2 2020 and has held it in 8 quarters since.
Truist Financial's Cytokinetics position peaked at $597K in Q4 2021.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.